FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment

Pallavi Madhiraju- October 13, 2024 0

In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI ... Read More

Eton Pharmaceuticals shocks investors with major acquisition: Shares explode to 52-week high

Pallavi Madhiraju- October 3, 2024 0

Eton Pharmaceuticals has sent shockwaves through the pharmaceutical industry after its shares soared to a 52-week high, fueled by the acquisition of the critical rare ... Read More

Avanzanite Bioscience secures EC approval for AKANTIOR as first authorised treatment for acanthamoeba keratitis

Pallavi Madhiraju- August 27, 2024 0

The European Commission (EC) has granted marketing authorisation for AKANTIOR (polihexanide), the first and only approved treatment for acanthamoeba keratitis (AK) globally, announced Avanzanite Bioscience ... Read More

Dr. Reddy’s Laboratories secures key European endorsement for Rituximab biosimilar

Pallavi Madhiraju- July 30, 2024 0

In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from the European Medicines Agency’s (EMA) Committee for ... Read More

EMA approves Dupixent as first biologic for COPD with elevated eosinophils

Pallavi Madhiraju- July 7, 2024 0

The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease ... Read More

CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment

Pallavi Madhiraju- June 9, 2024 0

CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More

Pfizer’s Vizimpro receives EMA approval recommendation for NSCLC treatment

pharmanewsdaily- February 3, 2019 0

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a significant boost to Pfizer's lung cancer drug, Vizimpro (dacomitinib), ... Read More